Syndax Pharmaceuticals Inc (NAS:SNDX)
$ 13.07 -0.24 (-1.8%) Market Cap: 1.12 Bil Enterprise Value: 710.08 Mil PE Ratio: 0 PB Ratio: 3.04 GF Score: 32/100

Syndax Pharmaceuticals Inc at Morgan Stanley Healthcare Conference Transcript

Sep 09, 2019 / 08:50PM GMT
Release Date Price: $8.82 (-0.56%)
David Neil Lebowitz
Morgan Stanley, Research Division - VP

(technical difficulty)

.com/researchdisclosures, or at the registration desk. And I'm one of our biotechnology analysts. My name is David Lebowitz, and I'd like to welcome to the stage with me from Syndax Pharmaceuticals, CEO, Briggs Morrison. Glad to have you back again.

Briggs W. Morrison
Syndax Pharmaceuticals, Inc. - CEO & Director

Good to see you, David.

David Neil Lebowitz
Morgan Stanley, Research Division - VP

Before we get started, I guess let's start with Syndax from a top level discussion. What's -- can you tell me about the company itself, where you came from and what your overall mission is.

Briggs W. Morrison
Syndax Pharmaceuticals, Inc. - CEO & Director

Sure. So our overall mission is to realize a future in which people with cancer live longer and better than ever before. And our overall business strategy is to license in molecules that we think have the potential to achieve

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot